CGEN.US Compugen

Healthcare Life Sciences Tools & Services USA Stocks
2.10 USD
Close of Nov 14, 2026
1.43 3.24
Market cap
USD 199M
P/E
5.4x
P/B
2.40x
ROE
-32.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CGEN.US undervalued?

Graham number
Price2.10
Graham value2.77
Discount24.2%

CGEN.US trades 24.2% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Compugen fundamental analysis

No fundamental analysis for Compugen yet.

Compugen stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy an…

Full company profile